Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01431209 · OUTCOME

Progression-free Survival

Ruxolitinib Phosphate to Treat Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma After Stem Cell Transplant · Source last updated 2023-10-05

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Months
Interval / dispersion
95% Confidence Interval
Time frame
From the date of start of treatment to the date of event defined as the first documented progression or death due to any cause, assessed up to 60 months.

What was measured

The Kaplan-Meier method will be used to estimate the median PFS time and its 95% CI.

Groups in this outcome

Diffuse Large B-cell Lymphoma (DLBCL)

Patients receive ruxolitinib phosphate PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Laboratory Biomarker Analysis: Correlative studies Ruxolitinib Phosphate: Given PO

Peripheral T-cell Non-Hodgkin Lymphoma (PTCL)

Patients receive ruxolitinib phosphate PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Laboratory Biomarker Analysis: Correlative studies Ruxolitinib Phosphate: Given PO

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Diffuse Large B-cell Lymphoma (DLBCL)47
Peripheral T-cell Non-Hodgkin Lymphoma (PTCL)13

Reported measurements

Source class 1
Values in Months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Diffuse Large B-cell Lymphoma (DLBCL)1.8Not reported1.11.8Not reported
Peripheral T-cell Non-Hodgkin Lymphoma (PTCL)2.2Not reported0.94.6Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        1.1
        upper Limit
        1.8
        value
        1.8
      2. group Id
        OG001
        lower Limit
        0.9
        upper Limit
        4.6
        value
        2.2
denoms
  1. counts
    1. group Id
      OG000
      value
      47
    2. group Id
      OG001
      value
      13
    units
    Participants
description
The Kaplan-Meier method will be used to estimate the median PFS time and its 95% CI.
dispersion Type
95% Confidence Interval
groups
  1. description
    Patients receive ruxolitinib phosphate PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Laboratory Biomarker Analysis: Correlative studies Ruxolitinib Phosphate: Given PO
    id
    OG000
    title
    Diffuse Large B-cell Lymphoma (DLBCL)
  2. description
    Patients receive ruxolitinib phosphate PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Laboratory Biomarker Analysis: Correlative studies Ruxolitinib Phosphate: Given PO
    id
    OG001
    title
    Peripheral T-cell Non-Hodgkin Lymphoma (PTCL)
param Type
MEDIAN
reporting Status
POSTED
time Frame
From the date of start of treatment to the date of event defined as the first documented progression or death due to any cause, assessed up to 60 months.
title
Progression-free Survival
type
SECONDARY
unit Of Measure
Months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice